Bioventus Inc. (NYSE:BVS) is Nantahala Capital Management LLC's 7th Largest Position

Nantahala Capital Management LLC decreased its stake in Bioventus Inc. (NYSE:BVS - Free Report) by 7.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,026,809 shares of the company's stock after selling 324,061 shares during the period. Bioventus makes up 1.8% of Nantahala Capital Management LLC's investment portfolio, making the stock its 7th largest holding. Nantahala Capital Management LLC owned 4.96% of Bioventus worth $42,281,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its stake in Bioventus by 106.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company's stock valued at $36,000 after purchasing an additional 1,786 shares in the last quarter. Plato Investment Management Ltd purchased a new position in shares of Bioventus in the fourth quarter valued at $38,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Bioventus in the 4th quarter worth about $75,000. Quantbot Technologies LP acquired a new stake in Bioventus in the 4th quarter valued at about $103,000. Finally, Arizona State Retirement System purchased a new position in Bioventus during the 4th quarter valued at about $109,000. Hedge funds and other institutional investors own 62.94% of the company's stock.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 price target on shares of Bioventus in a report on Monday, March 17th.

Insider Buying and Selling at Bioventus

In other news, SVP Anthony D'adamio sold 4,380 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the transaction, the senior vice president now owns 118,178 shares of the company's stock, valued at $1,204,233.82. This represents a 3.57 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Mark Leonard Singleton sold 5,479 shares of the firm's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $9.79, for a total transaction of $53,639.41. Following the completion of the sale, the chief financial officer now directly owns 131,963 shares in the company, valued at $1,291,917.77. This represents a 3.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 24,208 shares of company stock worth $226,138. Insiders own 32.90% of the company's stock.

Bioventus Trading Up 1.1 %

Shares of NYSE:BVS traded up $0.08 during trading on Friday, reaching $7.34. The stock had a trading volume of 377,946 shares, compared to its average volume of 453,096. Bioventus Inc. has a fifty-two week low of $3.94 and a fifty-two week high of $14.38. The business has a fifty day moving average price of $8.80 and a 200-day moving average price of $10.35. The stock has a market cap of $601.47 million, a P/E ratio of -12.03 and a beta of 0.92. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.